Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergoogle.co.in
Google Alert - evommune
Get the latest updates from Google Alert - evommune directly as they happen.
Follow now 107 followers
Latest posts
Last updated about 16 hours ago
Evommune scraps eczema drug after trial miss, shares plunge - Webull
about 23 hours ago
Securities trading is offered to self-directed customers by Webull Financial LLC, a...
stock setter on X: "$EVMN -Stifel maintains Evommune $30 target Buy
about 18 hours ago
EVMN -Stifel maintains Evommune $30 target Buy -Leerink lowers target to $22...
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use | BioPharma Dive
1 day ago
Today, a brief rundown of news involving Karyopharm Therapeutics and Amgen, as...
Evommune跌17%：MRGPRX2拮抗剂特应性皮炎2b期临床失败 - ByDrug - 医药魔方
1 day ago
ByDrug医药新闻摘要⌋ 2026-09-11 07:30，药渡：2026年9月9日，Evommune公布MRGPRX2拮抗剂EVO756治疗中至重度特应性皮炎2b期临床的顶线数据， ...
ทําไมหุ้น Evommune ถึงร่วงลง 13% ในวันนี้? - Investing.com
3 days ago
... Evommune ยืนยันว่าจะไม่นํา EVO756 ไปพัฒนาต่อในข้อบ่งชี้โรคผิวหนังอักเสบภูมิแพ้ แม้ว่าบริษัทยังคงตั้งใจดําเนินการทดลองระยะที่ 2b ต่อไปสําหรับการ ...
מדוע מניית Evommune צונחת ב-13% היום?
3 days ago
Investing.com -- מניית Evommune צונחת ב-13.9% במסחר קדם־שוק היום ומגיעה לרמה של...
RBC ปรับลดเป้าราคาหุ้น Evommune หลังการทดลองยาล้มเหลว - Investing.com
2 days ago
Investing.com - RBC Capital ปรับลดเป้าราคาหุ้น Evommune Inc (นิวยอร์ก:EVMN) ลงเหลือ $21 จาก $29...
EVMN) Discontinues EVO756 for Atopic Dermatitis, Sets EVO301 Phase 2b Trial for Mid-2027
2 days ago
Evommune will discontinue EVO756 development for atopic dermatitis but continue migraine prophylaxis...
EVMN) to Halt EVO756 Development for Atopic Dermatitis After Phase 2b Trial Failure, Cash ...
2 days ago
Evommune will continue clinical evaluation of EVO756 for migraine prophylaxis. The company's...
Evommune Inc Share News (EVMN) - Investing.com India
3 days ago
Evommune Inc (EVMN). NYSE. Currency in USD. Follow. Trade. 10.84. -2.24(-17.13%)...
Stifel reitera calificación de Evommune tras fracaso en ensayo fase 2b - Investing.com
3 days ago
En otros desarrollos recientes, Evommune Inc. anunció que su candidato a medicamento...
Stifel, faz 2b çalışması başarısız olduktan sonra Evommune hisse notunu korudu
2 days ago
Investing.com — Stifel, Evommune Inc (NYSE:EVMN) için Al notunu ve 30,00 dolar...